These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

548 related articles for article (PubMed ID: 27468920)

  • 1. Multicenter phase II study of combination therapy with cetuximab and S-1 in patients with KRAS exon 2 wild-type unresectable colorectal cancer previously treated with irinotecan, oxaliplatin, and fluoropyrimidines (KSCC 0901 study).
    Takahashi T; Emi Y; Oki E; Kobayashi K; Tsuji A; Shimokawa M; Tanaka T; Akagi Y; Ogata Y; Baba H; Yoshida K; Natsugoe S; Maehara Y;
    Cancer Chemother Pharmacol; 2016 Sep; 78(3):585-93. PubMed ID: 27468920
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II study of combination chemotherapy with biweekly cetuximab and irinotecan for wild-type KRAS metastatic colorectal cancer refractory to irinotecan, oxaliplatin, and fluoropyrimidines.
    Shitara K; Yuki S; Yoshida M; Takahari D; Utsunomiya S; Yokota T; Sato Y; Inaba Y; Tajika M; Kawai H; Yamaura H; Kato M; Yamazaki K; Komatsu Y; Muro K
    Invest New Drugs; 2012 Apr; 30(2):787-93. PubMed ID: 21174225
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multicenter Phase II study of FOLFOX or biweekly XELOX and Erbitux (cetuximab) as first-line therapy in patients with wild-type KRAS/BRAF metastatic colorectal cancer: The FLEET study.
    Soda H; Maeda H; Hasegawa J; Takahashi T; Hazama S; Fukunaga M; Kono E; Kotaka M; Sakamoto J; Nagata N; Oba K; Mishima H
    BMC Cancer; 2015 Oct; 15():695. PubMed ID: 26467662
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II trial of biweekly cetuximab and irinotecan as third-line therapy for pretreated KRAS exon 2 wild-type colorectal cancer.
    Osumi H; Shinozaki E; Mashima T; Wakatsuki T; Suenaga M; Ichimura T; Ogura M; Ota Y; Nakayama I; Takahari D; Chin K; Miki Y; Yamaguchi K
    Cancer Sci; 2018 Aug; 109(8):2567-2575. PubMed ID: 29908105
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CMAB009 plus irinotecan versus irinotecan-only as second-line treatment after fluoropyrimidine and oxaliplatin failure in KRAS wild-type metastatic colorectal cancer patients: promising findings from a prospective, open-label, randomized, phase III trial.
    Shi Y; Li J; Xu J; Sun Y; Wang L; Cheng Y; Liu W; Sun G; Chen Y; Bai L; Zhang Y; He X; Luo Y; Wang Z; Liu Y; Yao Q; Li Y; Qin S; Hu X; Bi F; Zheng R; Ouyang X
    Cancer Commun (Lond); 2019 May; 39(1):28. PubMed ID: 31126331
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Panitumumab in combination with irinotecan plus S-1 (IRIS) as second-line therapy for metastatic colorectal cancer.
    Takaoka T; Kimura T; Shimoyama R; Kawamoto S; Sakamoto K; Goda F; Miyamoto H; Negoro Y; Tsuji A; Yoshizaki K; Goji T; Kitamura S; Yano H; Okamoto K; Kimura M; Okahisa T; Muguruma N; Niitsu Y; Takayama T
    Cancer Chemother Pharmacol; 2016 Aug; 78(2):397-403. PubMed ID: 27342247
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Continuation of Bevacizumab vs Cetuximab Plus Chemotherapy After First Progression in KRAS Wild-Type Metastatic Colorectal Cancer: The UNICANCER PRODIGE18 Randomized Clinical Trial.
    Bennouna J; Hiret S; Bertaut A; Bouché O; Deplanque G; Borel C; François E; Conroy T; Ghiringhelli F; des Guetz G; Seitz JF; Artru P; Hebbar M; Stanbury T; Denis MG; Adenis A; Borg C
    JAMA Oncol; 2019 Jan; 5(1):83-90. PubMed ID: 30422156
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cetuximab plus capecitabine and irinotecan compared with cetuximab plus capecitabine and oxaliplatin as first-line treatment for patients with metastatic colorectal cancer: AIO KRK-0104--a randomized trial of the German AIO CRC study group.
    Moosmann N; von Weikersthal LF; Vehling-Kaiser U; Stauch M; Hass HG; Dietzfelbinger H; Oruzio D; Klein S; Zellmann K; Decker T; Schulze M; Abenhardt W; Puchtler G; Kappauf H; Mittermüller J; Haberl C; Schalhorn A; Jung A; Stintzing S; Heinemann V
    J Clin Oncol; 2011 Mar; 29(8):1050-8. PubMed ID: 21300933
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cetuximab plus irinotecan after irinotecan failure in elderly metastatic colorectal cancer patients: clinical outcome according to KRAS and BRAF mutational status.
    Fornaro L; Baldi GG; Masi G; Allegrini G; Loupakis F; Vasile E; Cupini S; Stasi I; Salvatore L; Cremolini C; Vincenzi B; Santini D; Tonini G; Graziano F; Ruzzo A; Canestrari E; Magnani M; Falcone A
    Crit Rev Oncol Hematol; 2011 Jun; 78(3):243-51. PubMed ID: 20619672
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FOLFIRI and Cetuximab Every Second Week for First-Line Treatment of KRAS Wild-Type Metastatic Colorectal Cancer According to Phosphatase and Tensin Homolog Expression: A Phase II Study.
    Personeni N; Rimassa L; Verusio C; Barni S; Rubino L; Bozzarelli S; Villa E; Carnaghi C; Tronconi MC; Gerardi C; Galli F; Floriani I; Destro A; Raschioni C; Labianca R; Santoro A
    Clin Colorectal Cancer; 2015 Sep; 14(3):162-9. PubMed ID: 25861836
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ICECREAM: randomised phase II study of cetuximab alone or in combination with irinotecan in patients with metastatic colorectal cancer with either KRAS, NRAS, BRAF and PI3KCA wild type, or G13D mutated tumours.
    Segelov E; Waring P; Desai J; Wilson K; Gebski V; Thavaneswaran S; Elez E; Underhill C; Pavlakis N; Chantrill L; Nott L; Jefford M; Khasraw M; Day F; Wasan H; Ciardiello F; Karapetis C; Joubert W; van Hazel G; Haydon A; Price T; Tejpar S; Tebbutt N; Shapiro J
    BMC Cancer; 2016 May; 16():339. PubMed ID: 27246726
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Maintenance Therapy With Cetuximab Every Second Week in the First-Line Treatment of Metastatic Colorectal Cancer: The NORDIC-7.5 Study by the Nordic Colorectal Cancer Biomodulation Group.
    Pfeiffer P; Sorbye H; Qvortrup C; Karlberg M; Kersten C; Vistisen K; Lindh B; Bjerregaard JK; Glimelius B
    Clin Colorectal Cancer; 2015 Sep; 14(3):170-6. PubMed ID: 25956187
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized, placebo-controlled, phase 1/2 study of tivantinib (ARQ 197) in combination with irinotecan and cetuximab in patients with metastatic colorectal cancer with wild-type KRAS who have received first-line systemic therapy.
    Eng C; Bessudo A; Hart LL; Severtsev A; Gladkov O; Müller L; Kopp MV; Vladimirov V; Langdon R; Kotiv B; Barni S; Hsu C; Bolotin E; von Roemeling R; Schwartz B; Bendell JC
    Int J Cancer; 2016 Jul; 139(1):177-86. PubMed ID: 26891420
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Initial Report of Phase II Study on Bi-weekly SOX plus Cetuximab Treatment for Wild-type K-RAS Advanced and Recurrent Colorectal Cancer.
    Ogawa M; Anan T; Suzuki T; Okuma M; Ichihara K; Hasegawa T; Yoshida K; Yanaga K
    Anticancer Res; 2016 May; 36(5):2505-11. PubMed ID: 27127165
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Phase II Study of Third-Line Combination Chemotherapy with Bevacizumab Plus S-1 for Metastatic Colorectal Cancer with Mutated KRAS (SAVIOR Study).
    Yoshida M; Takagane A; Miyake Y; Shimada K; Nagata N; Sato A; Ogata Y; Fukunaga M; Otsuka K; Takahashi T; Matsumoto H; Kagimura T; Tsuji A
    Oncology; 2016; 91(1):24-30. PubMed ID: 27229742
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and toxicity of adding cetuximab to chemotherapy in the treatment of metastatic colorectal cancer: a meta-analysis from 12 randomized controlled trials.
    Lv ZC; Ning JY; Chen HB
    Tumour Biol; 2014 Dec; 35(12):11741-50. PubMed ID: 25417200
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II trial of cetuximab plus irinotecan for oxaliplatin- and irinotecan-based chemotherapy-refractory patients with advanced and/or metastatic colorectal cancer: evaluation of efficacy and safety based on KRAS mutation status (T-CORE0801).
    Soeda H; Shimodaira H; Gamoh M; Ando H; Isobe H; Suto T; Takahashi S; Kakudo Y; Amagai K; Mori T; Watanabe M; Yamaguchi T; Kato S; Ishioka C
    Oncology; 2014; 87(1):7-20. PubMed ID: 24968756
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy, safety and genomic analysis of SCT200, an anti-EGFR monoclonal antibody, in patients with fluorouracil, irinotecan and oxaliplatin refractory RAS and BRAF wild-type metastatic colorectal cancer: a phase Ⅱ study.
    Yang L; Zhang W; Fan N; Cao P; Cheng Y; Zhu L; Luo S; Zong H; Bai Y; Zhou J; Deng Y; Ba Y; Liu T; Aili M; Yin X; Gu K; Dai G; Ying J; Shi J; Gao Y; Li W; Yu G; Xie L; Gai W; Wang Y; Meng P; Shi Y
    EBioMedicine; 2024 Feb; 100():104966. PubMed ID: 38217945
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomised phase II study of panitumumab plus irinotecan versus cetuximab plus irinotecan in patients with KRAS wild-type metastatic colorectal cancer refractory to fluoropyrimidine, irinotecan and oxaliplatin (WJOG 6510G).
    Sakai D; Taniguchi H; Sugimoto N; Tamura T; Nishina T; Hara H; Esaki T; Denda T; Sakamoto T; Okuda H; Satoh T; Tsushima T; Makiyama A; Tsuda T; Hosokawa A; Kuramochi H; Tokunaga S; Moriwaki T; Yasui H; Ishida H; Tsuji A; Otsu S; Shimokawa H; Baba E; Sato M; Matsumoto S; Ozaki Y; Shinozaki K; Tamagawa H; Goto M; Kadowaki S; Fujii H; Koh Y; Yamazaki K; Hironaka S; Kishimoto J; Boku N; Hyodo I; Muro K
    Eur J Cancer; 2020 Aug; 135():11-21. PubMed ID: 32526634
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II study of cetuximab with irinotecan for KRAS wild-type colorectal cancer in Japanese patients.
    Terazawa T; Nishitani H; Kato K; Hashimoto H; Akiyoshi K; Ito Y; Nakamoto A; Iwasa S; Nakajima TE; Hamaguchi T; Yamada Y; Shimada Y
    Asia Pac J Clin Oncol; 2017 Apr; 13(2):e132-e137. PubMed ID: 26245851
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.